Bacterial meningitis in the practice of a primary care physician. Clinical and immunological efficacy of recombinant interleukin-2 in the complex therapy of bacterial meningitis

The article analyzes the pathogenetic features of bacterial meningitis and substantiates the scheme of complex therapy of the disease using the recombinant cytokine interleukin-2 (IL2). The clinical, immunological and microbiological efficacy of the complex therapy scheme has been revealed. It has been shown that the pleiotropic effects of recombinant IL-2, its effect on the activity of metabolic processes at the cellular and subcellular levels, the ability to stabilize the system of lipid peroxidation of cell membranes, the ability to influence the processes of clonal proliferation and differentiation of T- and B-lymphocytes, make its use justified in complex therapy of meningitis.

Generalization of information substantiating the method of subcutaneous administration of recombinant human interleukin-2

The article presents the experience and clinical and immunological effectiveness of the use of recombinant human interleukin-2. The accumulated clinical experience of the use of recombinant interleukin-2 in patients of different age groups indicates the validity and expediency of including the drug in the basic therapy of severe bacterial and viral infections, oncological diseases, simultaneously with antimicrobial chemotherapy in order to normalize immunological parameters and improve the clinical course of the disease, as well as for timely and complete resolution of the inflammatory process.

Clinical and immunological and microbiological effectiveness of the use of recombinant interleukin 2 in the complex therapy of bacterial meningitis

The article shows the scheme of complex therapy of bacterial meningitis using the recombinant cytokine interleukin 2. The clinical, immunological and microbiological efficacy of the use of recombinant interleukin 2 in the complex therapy of bacterial meningitis is shown. The biological effects of recombinant IL-2 justify its use in the complex therapy of meningitis due to its influence on the activity of metabolic processes at the cellular and subcellular levels, the ability to stabilize the system of lipid peroxidation of cell membranes, to influence the processes of clonal proliferation and differentiation of T- and B-lymphocytes improving the quality of the therapy.

Recombinant cytokines in the practice of the therapist

The article contains information presented in the open press based on the results of studies of the clinical efficacy of recombinant interleukin 2. Roncoleukin provides immune protection against tumor cells, pathogens of viral, bacterial and fungal nature, activates the processes of tissue repair and regeneration, promotes adequate interaction of the immune, endocrine and nervous systems. Interleukin-2 is an activation, proliferation and differentiation factor for T- and B-lymphocytes, T-regulatory cells, natural killer cells, monocytes / macrophages, dendritic and oligodendroglial cells; protects activated T cells from premature death (apoptosis) and cancels immunological tolerance.

Effects of Apigenin, Luteolin, and Quercetin on the Natural Killer (NK-92) Cells Proliferation: A Potential Role as Immunomodulator

Cancer can be classified as a fourth leading cause of death in Malaysia. There is a continuous effort by scientists in finding alternative cure to cancer due to the known side effects of chemotherapy and radiation therapy as well as recurrences. One of the latest methods to kill cancerous cells is by using immune cells known as natural killer (NK) cells. Flavonoids such as flavone and flavonol are also known for their antioxidant, anti-inflammatory, immunomodulatory and anticancer properties. This study was carried out to determine the role of flavonoid compounds of apigenin, luteolin, and quercetin to facilitate the growth of NK-92 cells. NK-92 cell line was grown in tissue culture flasks containing α- Minimum Essential Medium (MEM) medium enriched with L-glutamine, 12.5% fetal bovine serum, 12.5% horse serum, 0.2 mM myo-inositol, 0.02 mM folic acid, and 100 - 200 U/mL recombinant interleukin 2 (IL-2). The cell viability was determined via trypan blue staining where the cells were manually counted by a haemocytometer. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to determine the cell viability of NK-92 cells after treatment with apigenin, luteolin, and quercetin. Results showed a dose-dependent proliferative effects of apigenin, luteolin, and quercetin on the proliferation of NK-92 cells showing the highest percentage of proliferation at 100 μg/mL for all compounds (*P < 0.05). However, exceeding the dose of 100 μg/mL had resulted in a decline of cell proliferations percentage. Based on these findings, flavonoid compounds comprising apigenin, luteolin and quercetin were able to induce proliferative effects on NK-92 cells.

MED-12-2103-02

Currently, one of the priority medical and social problems of medicine is to optimize the treatment of bacterial skin infections, in particular pyoderma associated with Streptococcus pyogenes-group A streptococcus. The traditional treatment complex, including antibacterial drugs used systemically or topically, selected taking into account individual sensitivity, the presence of pathognomonic microflora, is not always effective due to the increase in antibiotic resistance. Currently implemented methods of immunocorrection, taking into account changes in the immune status in this pathology, corresponding to the clinic of patients, are pathogenetically justified and can be effective. The use of immunomodulatory therapy requires a change in approaches to diagnosis, clarifying the role of factors of innate and adaptive immunity, intercellular mediators and the system of antioxidant protection, allowing to optimize the methods of treatment of this pathology. The use of recombinant interleukin-2 makes up for the lack of interleukin-2 in the blood serum of patients with streptoderma and contributes to the clinical recovery of patients.

The experience of the combined use of Roncoleukin® and Viferon® in the treatment of patients with COVID-19

The article presents the results of the clinical use of Roncoleukin® (recombinant interleukin-2) and Viferon® (interferon alfa-2b) in the complex treatment of more than 300 patients with COVID-19 in outpatient and inpatient conditions from May to December 2020 in various regions of Russia and abroad. The obtained results indicate a dramatic improvement in the condition of patients with the inclusion of Roncoleukin® and Viferon® in the COVID-19 treatment regimen, which made it possible to achieve patient recovery in all cases and avoid death among patients with severe COVID-19. The article justifies the necessity of compulsory use of interleukin-2 and interferon alpha-2b in the treatment regimen of COVID-19 patients as the factors determining the timely activation of specific immune responses that block the growth of nonspecific immune reactions leading to the generalization of infectious and inflammatory processes (“cytokine storm”), decompensation of chronic diseases and death. The need to normalize the psychoemotional state as an important pathogenetically significant factor that has a considerable impact on both the course of coronavirus disease and its outcome is demonstrated.